Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
he US FDA has issued six observations pursuant to the completion of the audit.
He was appointed a Board member and the Chairman in 2012.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Subscribe To Our Newsletter & Stay Updated